Investors who were lucky enough to secure an allotment in the recent Initial Public Offering (IPO) of Sopan Pharmaceuticals Limited (SOPAN) received fantastic news today. The Nepal Stock Exchange (NEPSE) officially listed the company’s shares on June 5, 2026 (Jestha 22, 2083), paving the way for secondary market trading to begin next week.
A total of 2,200,000 units of equity shares have been listed on the exchange floor. Here is a breakdown of what to expect when the opening bell rings and how the valuation shapes up.
The Core Numbers & Opening Range
When a company lists on NEPSE for the first time, its initial trading price isn’t random. NEPSE sets an opening price range based on the company’s audited net worth per share from the previous fiscal year. The lower limit is equal to the net worth, while the upper limit is exactly three times that amount.
For Sopan Pharmaceuticals, NEPSE has locked in the following critical trading bounds for the special pre-open session:
Ticker Symbol: SOPAN
Total Listed Shares: 2,200,000 units
Lower Range Limit: Rs. 100.00
Upper Range Limit: Rs. 300.00
This means the very first transaction in the special pre-open session (which happens between 10:30 AM and 10:45 AM on the first trading day) must match a price within the Rs. 100.00 to Rs. 300.00 bracket. If a buyer and seller successfully match an order within this window, continuous regular trading can begin at 11:00 AM.
About Sopan Pharmaceuticals Limited
For investors looking closely at sector allocations, Sopan Pharmaceuticals represents a crucial and growing niche in NEPSE: the domestic pharmaceutical production market.
Incorporated in 2016 and transitioning to a public entity in late 2021, the company operates out of a modern manufacturing facility located in Mahalaxmi-05, Lalitpur. Sopan manufactures and markets a diverse catalog of over 40 distinct pharmaceutical formulations. Their lineup covers heavily consumed therapeutics across categories such as:
Antibiotics and antifungals
Gastrointestinal treatments
Cardiovascular drugs
Anti-diabetic medications
Analgesics and antihistamines
Credit Rating and Investor Outlook
Before trading kicks off, it is worth looking back at the company’s recent risk assessment. Care Ratings Nepal Limited (CRNL) assigned a CARE-NP BB (Is) rating to Sopan Pharmaceuticals.
Investor Insight: This specific rating indicates a moderate risk of default regarding timely servicing of financial obligations. While it signals that the company is exposed to standard industry headwinds, it also reflects steady market standing as they scale their manufacturing footprints to grab a larger market share of Nepal’s domestic medicine demand.
What Should Investors Do?
If you hold shares of SOPAN through the IPO allotment, you will likely see them appear in your MeroShare Demat account under the symbol “SOPAN” over the weekend.
Given the massive demand and low float of shares in Nepal’s primary market, initial listings in healthy consumer sectors often experience consecutive days of hitting the upper circuit limit (a 10% daily price increase). Long-term investors may choose to hold on to see how the company utilizes its new capital injection, while short-term traders generally look to capitalize on early market momentum.
